Tag #Mrna

Showing 1 to 6 of 6 results

forbes.com

🌐 85% Global Worthiness

Aug 26, 16:20

Innovative HIV Cure Approaches Show Promise in Trials

Building on the success of stem cell transplants, innovative HIV cure approaches like combination therapies (including mRNA delivery and novel antibodies) and gene therapies are showing promise in trials, particularly in children and early-diagnosed adults, offering hope for a widely accessible cure...

Innovative HIV Cure Approaches Show Promise in Trials

Building on the success of stem cell transplants, innovative HIV cure approaches like combination therapies (including mRNA delivery and novel antibodies) and gene therapies are showing promise in trials, particularly in children and early-diagnosed adults, offering hope for a widely accessible cure...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the most promising avenues for developing a widely applicable HIV cure, considering the limitations of existing methods?

Ten individuals have been cured or are in long-term remission from HIV via stem cell transplantation, a complex procedure with limited wider applicability. A recent trial, FRESH, showed promise with a novel drug and antibody combination resulting in four women in remission, one potentially cured.

welt.de

🌐 85% Global Worthiness

Jun 13, 07:12

BioNTech to Acquire CureVac, Boosting Tübingen's Biotech Hub

BioNTech, a Mainz-based pharmaceutical company, plans to acquire its Tübingen-based rival CureVac in a multi-billion euro deal, aiming to expand mRNA-based cancer immunotherapy research and development in Tübingen, strengthening the region's biotech hub and securing high-skilled jobs.

BioNTech to Acquire CureVac, Boosting Tübingen's Biotech Hub

BioNTech, a Mainz-based pharmaceutical company, plans to acquire its Tübingen-based rival CureVac in a multi-billion euro deal, aiming to expand mRNA-based cancer immunotherapy research and development in Tübingen, strengthening the region's biotech hub and securing high-skilled jobs.

Progress

44% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What is the immediate impact of BioNTech's planned takeover of CureVac on Tübingen's biotech sector and Germany's innovation landscape?

BioNTech's planned acquisition of CureVac will strengthen Tübingen's position as a biotech hub, securing high-skilled jobs and boosting mRNA-based cancer immunotherapy research and development. The deal, expected to be worth billions, follows BioNTech's success with a COVID-19 vaccine while CureVac's efforts were unsuccessful.

theguardian.com

🌐 90% Global Worthiness

Jun 5, 10:14

New mRNA Delivery Method Shows Potential for HIV Cure

Australian researchers developed a new mRNA delivery method using specially formulated lipid nanoparticles (LNP X) to reveal hidden HIV in white blood cells, potentially paving the way for a cure and impacting the 40 million people globally living with HIV.

New mRNA Delivery Method Shows Potential for HIV Cure

Australian researchers developed a new mRNA delivery method using specially formulated lipid nanoparticles (LNP X) to reveal hidden HIV in white blood cells, potentially paving the way for a cure and impacting the 40 million people globally living with HIV.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the new mRNA delivery method using LNP X potentially contribute to an HIV cure, considering the global impact of the disease?

Researchers at the Peter Doherty Institute have developed a new mRNA delivery method using lipid nanoparticles (LNP X) to reveal hidden HIV in white blood cells, a significant hurdle in developing an HIV cure. This method successfully targeted cells previously unreachable by mRNA, showing potential for eliminating the virus reservoir.

elpais.com

🌐 85% Global Worthiness

Jun 19, 22:15

mRNA-Based Immunotherapy Shows Promise, Potentially Lowering CAR-T Therapy Costs

A new mRNA-based immunotherapy treatment, developed by Carl June and colleagues at the University of Pennsylvania and Capstan, shows promise in treating autoimmune diseases and leukemia in preclinical trials, potentially lowering the cost to around €5,000 per dose.

mRNA-Based Immunotherapy Shows Promise, Potentially Lowering CAR-T Therapy Costs

A new mRNA-based immunotherapy treatment, developed by Carl June and colleagues at the University of Pennsylvania and Capstan, shows promise in treating autoimmune diseases and leukemia in preclinical trials, potentially lowering the cost to around €5,000 per dose.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of this new mRNA-based CAR-T therapy, and how could it impact global healthcare access to cancer and autoimmune disease treatments?

A new immunotherapy treatment using lipid nanoparticles and messenger RNA (mRNA) has successfully treated leukemia in mice and rats, and autoimmune diseases in cell cultures. The treatment, developed by Carl June and colleagues, aims to significantly reduce the cost of CAR-T therapies, potentially making them accessible to more patients. This new approach may avoid permanent genetic changes, offering a safer alternative.

dw.com

🌐 85% Global Worthiness

Jun 12, 19:11

BioNTech to Acquire Curevac for $1.25 Billion

BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.

BioNTech to Acquire Curevac for $1.25 Billion

BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the strategic significance of BioNTech's acquisition of Curevac for the global cancer treatment landscape?

BioNTech, a German biotech firm co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, offered to acquire its competitor Curevac for approximately $1.25 billion. The deal aims to strengthen BioNTech's mRNA-based cancer treatment capabilities and is expected to close by the end of 2025. Curevac shareholders are projected to own 4-6% of BioNTech after the acquisition.

bbc.com

🌐 85% Global Worthiness

Mar 11, 16:09

COVID-19 Pandemic: Positive Impacts Five Years On

Five years after the WHO declared a COVID-19 pandemic, resulting in over 777 million infections and 15 million deaths, positive aspects emerged, including rapid mRNA vaccine development, educational shifts towards digitalization, and increased awareness of mental health importance.

COVID-19 Pandemic: Positive Impacts Five Years On

Five years after the WHO declared a COVID-19 pandemic, resulting in over 777 million infections and 15 million deaths, positive aspects emerged, including rapid mRNA vaccine development, educational shifts towards digitalization, and increased awareness of mental health importance.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the pandemic affect the fields of education and work, and what long-term changes might these shifts bring?

The rapid development of mRNA vaccines exemplifies the pandemic's positive impact on scientific innovation. This technology, accelerated by the pandemic's urgency, now holds promise for future disease prevention. Simultaneously, the crisis forced a reevaluation of education and work models, leading to increased digitalization and flexibility.

Showing 1 to 6 of 6 results